Ⅰ-ⅢA期非小细胞肺癌KRAS基因突变与ERCC1、TYMS mRNA表达水平的相关研究  

Correlation of KRAS Mutations with the m RNA Expression Levels of ERCC1 and TYMS in StageⅠto ⅢA Non-small Cell Lung Cancer

作　　者：任保瑞[1] 朱彦君[2] 王桂洪[2] 伍青[2] 张希东[2] 吴科[2] 刘颖汇[2] 

机构地区：[1]安徽医科大学,安徽合肥230032 [2]安徽医科大学空军临床学院,安徽合肥230032

出　　处：《现代生物医学进展》2016年第10期1833-1837,共5页Progress in Modern Biomedicine

基　　金：卫生部医药卫生科技发展研究中心基金项目(W2011FAI13)

摘　　要：目的:探讨Ⅰ-ⅢA期非小细胞肺癌(NSCLC)KRAS基因突变与核苷酸切除修复交叉互补基因1(ERCC1)、胸苷酸合成酶(TYMS)mRNA表达水平的相关性及其与患者临床病理特征的关系。方法:收集空军总医院胸外科2010年06月至2014年10月符合入组条件的Ⅰ-ⅢA期NSCLC患者69例,肺癌组织标本均为手术中切取,KRAS基因突变应用x TAG-液相芯片法检测,ERCC1、TYMS mRNA表达水平应用分支DNA-液相芯片法检测。结果:在69例检测样本中,共有13例存在KRAS基因突变,突变率为18.8%(13/69);男性患者中KRAS基因突变率(29.3%,12/41)较女性患者(3.6%,1/28)高(P=0.007)。ERCC1 mRNA的表达水平与病理类型、吸烟史、有无淋巴结转移、临床TNM分期相关(P<0.05),TYMS mRNA表达水平与患者各临床病理特征无关(P>0.05)。KRAS突变型患者ERCC1 mRNA表达水平比KRAS野生型患者高(P<0.05),KRAS基因突变与TYMS mRNA表达水平无关(P>0.05)。结论:在Ⅰ-ⅢA期NSCLC患者中,男性患者更容易发生KRAS突变。KRAS突变型患者可能不能从铂类化疗药物中受益,有利于指导早中期NSCLC患者术后的个体化治疗。Objective： To investigate whether KRAS gene mutations are correlated with the m RNA expression levels of excision repair cross-complementing 1（ERCC1） and thymidylate synthetase（TYMS） in stageⅠto ⅢA non-small cell lung cancer（NSCLC）,and their relationship with clinical and phathological characteristics of NSCLC patients. Methods： A total of 69 patients with stageⅠto ⅢA NSCLC from Thoracic Surgery of Air Force General Hospital are collected from June 2010 to October 2014. Lung cancer tissues were obtained by intraoperative cut. KRAS mutations were detected with x TAGliquid chip technology（x TAG-LCT）, and m RNA expression levels of ERCC1 and TYMS genes were detected by branched DNA-liquidchip technology（b DNA-LCT）. Results： Of 69 casess, 13 cases were positive for KRAS mutations, the mutation rate was 18.8%（13/69）. KRAS gene mutations in male patients had a higher detection rate（29.3%, 12/41） than detection rate（3.6%,1/28） in female patients（P = 0.007）. The m RNA expression levels of ERCC1 gene were relevant to the pathological type, smoking,lymph node metastasis and clinical TNM stage. The m RNA expression levels of TYMS gene were not relevant to clinical and phathological characteristics of NSCLC patients. The m RNA expression levels of ERCC1 gene in the NSCLC patients with KRAS mutations were higher than those in patients with wild-type KRAS（P〈0.05）. KRAS mutations were not relevant to the m RNA expression levels of TYMS gene. Conclusions： In stage Ⅰ to Ⅲ A NSCLC patients, KRAS mutations are more frequent in men. The patients with KRAS mutations may not benefit from platinum-based chemotherapy.This will help us guide individualized treatment in the early and mid NSCLC patients with operation.

关 键 词：非小细胞肺癌 KRAS 核苷酸切除修复交叉互补基因1 胸苷酸合成酶 化疗 

分 类 号：R734.2[医药卫生—肿瘤]